Cerebral venous sinus thrombosis (CVST) is an uncommon location of venous thromboembolism (VTE) that represents a distinct cause of stroke primarily affecting young adults. 1,2 Predisposing factors for CVST are multiple, including those described in VTE and specific local causes (regional infections, brain tumors, and cranial trauma). 3 Beyond thrombosis, CVST-related parenchymal injuries include edema, ischemic strokes, and intra-cerebral hemorrhage (ICH; i.e., parenchymal/subdural hematomas and subarachnoid hemorrhages), which are identified in 40%-60% of patients. [4][5][6][7] Diagnosis and prognosis are still challenging due to the non-specificity and high variability of clinical course. Clinical symptoms result from increased intracranial pressure due to impaired venous drainage and CVST-related brain injury. Clinical symptoms range from isolated headaches (the most frequent one at presentation ≈90%), to focal deficits, seizure, and coma. 4,5,7,8 Recent studies reported higher incidence of CVST than previously estimated (13-17.5 vs. 3-5 million per year, respectively) with an overall death and dependency rate ≈15%. 1,2,6 This may be the result, at least in part, of the improved